Our Team

Your gateway to rxilient,
Get in touch with us

Over 15 years of extensive worldwide regulatory experience.
During his tenure at Bayer, Dr. He excelled as a global regulatory leader, successfully filed and received NDA approvals from 30+ countries including the US, EU, APAC, MENA, Japan, China, and Latin America.
Dr. He was the VP of regulatory affairs at Transcenta, where he successfully led teams in completing multiple INDs/CTAs and milestone submissions in the US and China.
During time at Inmagene Biopharmaceuticals, Dr. He was SVP, regulatory affairs and project management, where he founded and led the RA and PM team and achived major development milestones (IND/CTA approval, authority meetings, study initiation, etc) in multiple countries including the US, EU, Australia, and China.
Dr. He’s contributions extended beyond regulatory strategy, encompassing authority meetings, FDA advisory committee preparation, KOL communication, due diligence assessment, and project management.
Dr. He holds a Doctor of Medicine (M.D.) from Peking Union Medical College, a Master of Public Health (M.P.H.) from Harvard University T.H. Chan School of Public Health, and undergraduate in premed from Peking University School of Life Sciences.

Esteemed executive boasting over 25 years of comprehensive regional and country leadership roles across multiple multinational pharmaceutical giants.
Dedicated 17 transformative years at LEO Pharma, culminating as the Senior Area Director for South Asia, navigating diverse managerial responsibilities.
Helmed strategic initiatives across 12 countries and was instrumental in driving commercial strategies that spurred regional growth.
An alumnus of the University of London and INSEAD, proudly holds a Bachelor of Science (Hons) degree and a Certificate in Global Management.

Extensive financial experience in US-GAAP audit and internal control, M&A advisory, investment due diligence, and post-investment financial management.
Prior to joining Rxilient, Chelsea served as financial consultant at Legend Capital with the roles of financial risk assessment on investment targets and post-investment financial management support to portfolio companies.
Before that, Chelsea worked as senior manager at PwC, advising more than 20 companies on their transactions ranging from minority investments to mergers and acquisitions. During her career in PwC, she also performed audit for companies listed on Nasdaq.
Chelsea is a licensed CICPA. She received a master’s degree in Chemistry from University of Western Ontario, and a bachelor’s degree in Chemistry from Nankai University.

Dynamic leader with extensive experience of 40 years in the pharmaceutical industry in the Middle East, GCC, and Africa.
Expertise lies in establishing businesses, finding the right partners, and successfully expanding operations.
Pursued a diverse set of qualifications and he is a pharmacist holds a Diploma in Management from the United Kingdom. Complementing this, he earned a Diploma in Human Resources from the American University in Cairo (AUC) and a Diploma in Organizational Leadership from Lausanne, Switzerland.

Extensive experience in healthcare and business development leadership roles at companies like Everest Medicine, ArkBio, and Terns Pharmaceuticals.
Background includes positions in financial advisory, investor relations, and consulting at Rayo Advisors, TPP Healthcare, Amgen, Yifan Pharma, and Gloria Pharma.
Holds a bachelor’s degree in Pharmaceutics from China Pharmaceutical University, a PhD in Pharmaceutical Sciences from the University of the Pacific, and an MBA from San Jose State University.
Chartered Financial Analyst (CFA), Project Management Professional (PMP), and licensed pharmacist in China.

Wynstan brings a diverse background with significant roles at various pharmaceutical companies.
Supported Commercial operations in Mainland China, Taiwan, and Hong Kong at Astellas China, oversee Sales Force Effectiveness, Digital Operations, and Sales Learning & Development for Immunology and Oncology products.
Managed Portfolio and Strategy Planning at Ferring Pharmaceutical China where Wynstan was responsible for portfolio management, business strategy, and strategic workforce planning. Prior to this, Wynstan led the Business Analysts and Market Research team for Janssen Pharmaceutical China and served as Head of Business Unit at Janssen Pharmaceutical Hong Kong.
Holds a BSc in Microbiology, a Master of Philosophy in Cellular Pathology, and a Master of Social Science in Counselling.

Rui brings extensive regulatory affairs and global end-to-end API/DP product supply management having held global, regional and local roles from Bayer, MSD, and Pfizer.
At Bayer, Rui led regulatory strategies for Cardiovascular, Nephrology, and Oncology portfolios, achieving 30+ NDA approvals across 13 APAC countries (Australia, S. Korea, India, ASEAN, Taiwan and others). Rui also accelerated approvals through innovative pathways such as Reliance, ACCESS and Project Orbis. In addition, Rui served as Global CMC Lead for multiple pharmaceutical products as well as antibody and antibody–drug conjugate (ADC) products in development, supporting multiple GMP inspections on site.
At MSD, Rui developed CMC strategies for over 20 NDA submissions across 10+ APAC markets and drove regional regulatory policy advocacy initiatives.
At Pfizer, Rui managed API/DP External supply across multiple APAC suppliers, supporting over USD $500 million in annual sales and successfully launching key injectables from Pfizer’s first China CMO into EU markets.

Rui holds a Bachelor‘s degree in Pharmaceutical Science (B.Sc.) from Peking University, a Master of Philosophy (M. Phil.) in Pharmacology from University of Hong Kong and a Ph.D. in Molecular and Cellular Biology from Stony Brook University. Rui is also Regulatory Affairs Certification (RAC)-certified.

Over 10 years of extensive legal experiences in cross-border transactions.
During his Journey at Country Garden Dr. Zhang act as head of legal in regional company, successfully structured the team from 0 to 1 and was leading in the acquiring various projects.
Dr. Zhang was Senior Associate in ZHONG LUN Law firm (Beijing) and lead many challenging oversea investment projects mainly M&A and Mining investment projects.
Dr. Zhang was acting as head oversea legal head including compliance matters during his role in a top multi-national developer, and is experience in legal management involving cross culture communications.